Status:
COMPLETED
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free...
Eligibility Criteria
Inclusion
- Inclusion Criteria - Stage IV breast cancer patients
- Patient age must be \> 21 years.
- Patient must have a tissue diagnosis of invasive breast cancer.
- Patient must have documented evidence of metastatic disease.
- Patient must have measurable lesions.
- Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
- Patient must have an ECOG performance status of 0, 1, or 2.
- Patient must be available for follow-up.
- Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
- The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
- Inclusion Criteria - Healthy volunteers
- A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
- Volunteer age must be \> 21 years.
- Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
- Patients with benign breast disease are eligible for enrollment.
- The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
Exclusion
- Exclusion Criteria - Stage IV breast cancer patients
- A patient will be ineligible for inclusion in this study if ANY of the following criteria apply:
- No documented metastatic disease.
- No measurable lesions.
- Bone only and/or brain metastasis.
- Patient is not initiating a new regimen of systemic therapy.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT00355316
Start Date
November 1 2005
End Date
February 1 2013
Last Update
June 21 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
2
Medical University of South Carolina
Charleston, South Carolina, United States, 29425